Actinogen Medical Limited (ASX: ACW)
Health Care · Biotechnology · AU
AU$0.06
+1.85% today · +77.4% 1Y
Actinogen Medical Limited (ASX: ACW) operates in the Biotechnology industry within the Health Care sector. The company is valued at $147.68M and employs 6 people.
Over the last twelve months the share price has gained 77.4%, trading between 0.03 and 0.07.
Tweenvest scores Actinogen Medical Limited across four factors: quality 38/100, value 64/100. Its strongest factor is value.
ACW price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $147.68M
- Revenue (TTM)
- $8.77M
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.83
- 52-week high
- AU$0.07
- 52-week low
- AU$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 3.85B
- Employees
- 6
- Next earnings
- —
About Actinogen Medical Limited
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
- ISIN
- AU000000ACW3
- Founded
- 1999
- Listed since
- Oct 16, 2007
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Minerva Neurosciences, Inc.NasdaqCM: NERV | $151.84M | $2.89 | -9.12% |
| Essex Bio-Technology LimitedSEHK: 1061 | $149.73M | HK$2.08 | -3.26% |
| Scancell Holdings plcAIM: SCLP | $149.18M | £0.09 | +0.54% |
| Molecular Partners AGSWX: MOLN | $148.00M | CHF3.21 | -3.60% |
| JW (Cayman) Therapeutics Co. LtdSEHK: 2126 | $146.12M | HK$2.83 | +5.21% |
| Acumen Pharmaceuticals, Inc.NasdaqGS: ABOS | $146.08M | $2.02 | -5.61% |
| CANbridge Pharmaceuticals Inc.SEHK: 1228 | $145.79M | HK$1.92 | -6.59% |
| Kangstem Biotech Co., Ltd.KOSDAQ: A217730 | $144.47M | ₩2,065.00 | -7.81% |
Figures last refreshed Oct 11, 2026.